Why hip osteoarthritis injections follow a step-wise ladder

If you have been told that injections can help your hip, the next question is almost always: which one, and why?

The hip is a deep ball-and-socket synovial joint — the head of the femur sits inside the acetabulum, surrounded by cartilage and bathed in synovial fluid. Because of that depth, reaching the joint at all requires image guidance, and because osteoarthritis erodes that cartilage in stages, no single injection addresses every stage equally well.

This is the logic behind the hip injection ladder. Each rung represents a distinct biological approach, a different patient profile, and a different treatment goal. Moving up the ladder is not a sign that the previous step failed; it reflects a closer match between the treatment and where a patient's hip actually is in the disease process.

The three rungs covered in this article are: corticosteroid injection, which targets acute joint inflammation; hyaluronic acid viscosupplementation, which restores the lubricating quality of synovial fluid in mild-to-moderate osteoarthritis; and ChondroFiller injection, an ultrasound-guided collagen scaffold treatment designed to support biological repair of focal cartilage defects. These are not simply stronger versions of one another — they act through entirely different mechanisms and are suited to different clinical situations.

Ultrasound guidance is used across all three rungs at Lincolnshire Hip, given the depth of the hip joint and the precision that intra-articular placement demands.

Corticosteroid injections for hip pain: the first rung

Corticosteroid injections have earned their place at the bottom of the ladder because they work quickly and reliably for what they are designed to do. Formulations commonly used in the hip joint include triamcinolone, betamethasone, and methylprednisolone — all administered intra-articularly to suppress the inflammatory response inside the joint. Most patients notice relief within a few days, and the treatment is widely available, including on the NHS, at low cost.

The appropriate uses for a hip corticosteroid injection are specific: an acute inflammatory flare where rapid pain reduction allows the patient to function, or as a diagnostic step to confirm that the hip joint itself — rather than the lower back, sacroiliac joint, or trochanteric bursa — is the true source of the pain. A clear, sustained response to a well-placed intra-articular steroid is useful clinical information in its own right.

The limitation that shapes its position on the ladder is chondrotoxicity. A systematic review by Wernecke et al. (2015) documented adverse effects of intra-articular corticosteroids on articular cartilage, and Dragoo et al. (2012) reported that even a single dose can carry cartilage-level risk. Repeated courses over months may affect the very cartilage surface that later treatments would aim to protect. For this reason, corticosteroid injection is best understood as a short-term or diagnostic tool rather than a routine strategy for managing hip osteoarthritis from month to month.

Hyaluronic acid injections for hip OA: the second rung

Where corticosteroid reduces inflammation quickly, hyaluronic acid works differently — it replenishes the joint fluid that cushions and lubricates the hip. In a healthy synovial joint, the fluid contains naturally occurring hyaluronan that gives it its characteristic viscosity and shock-absorbing quality; in hip osteoarthritis, that fluid becomes thinner and less effective, contributing to friction and pain. Viscosupplementation replaces what is lost.

HA injections are indicated for mild-to-moderate hip OA — the clinical gap where a steroid can quieten a flare but does not provide sustained benefit, and where surgery remains premature. A landmark randomised controlled trial by Qvistgaard et al. (Osteoarthritis & Cartilage, 2006) compared intra-articular HA, corticosteroid, and isotonic saline directly in the hip joint, finding sustained benefit in favour of HA at longer follow-up. Spitzer et al. (2010) demonstrated in a prospective randomised study that Hylan G-F 20, a cross-linked HA formulation, improves hip OA outcomes. De Lucia et al. (2019, Frontiers in Pharmacology) found that repeated courses of viscosupplementation are effective and well tolerated in symptomatic hip OA, with high-molecular-weight formulations showing advantage over medium-molecular-weight alternatives — a distinction relevant to product choice. Effects typically last around six months, and repeat courses are generally required to maintain benefit.

UK patients may recognise brand names such as Durolane, Synvisc, Ostenil, and Hyalgan — all HA-based viscosupplements, differing in molecular weight and injection schedule.

The important limitation of this rung is that HA is a lubricant, not a repair agent. It supports symptom management and quality of life in suitable patients, but it does not restore lost cartilage tissue.

ChondroFiller injection: the regenerative third rung

The third rung asks a different clinical question altogether. Rather than managing symptoms or lubricating a deteriorating surface, the aim of a ChondroFiller injection is biological regeneration — supporting the formation of new cartilage tissue within a focal defect in the hip joint.

ChondroFiller (Meidrix Biomedicals GmbH) is a CE-marked Class III medical device: a sterile type I/III collagen scaffold delivered in liquid form under ultrasound guidance directly into the mapped cartilage defect. Once injected, the material sets into a gel in situ within minutes, physically occupying the defect rather than dispersing into the joint cavity as a lubricant would. The scaffold then acts as a biological invitation: the patient's own progenitor cells migrate in, mature into chondrocytes, and progressively lay down new cartilage matrix — a process termed matrix-induced chondrogenesis. Over approximately 6 to 12 months, the collagen scaffold degrades as that new tissue forms.

For the hip joint specifically, published evidence includes Perez-Carro et al. (2021), and across more than 20,000 implantations accumulated over a decade, MOCART imaging scores of 70 to 87 have been recorded, with outcomes maintained at five years in suitable patients. Clinicians reviewing ChondroFiller for hip applications should note that the bulk of longer-term randomised controlled trial data derives from non-hip joints, notably the knee — a limitation worth acknowledging when counselling patients, even as the hip-specific data continues to develop.

At Lincolnshire Hip, ChondroFiller injection is offered as an outpatient, ultrasound-guided procedure — not surgery, not keyhole, not theatre-based. The depth and anatomy of the hip joint make ultrasound guidance important for accurate placement, and image-guided delivery is standard across all three rungs of the ladder at this service.

There is no upper age limit for candidacy, and the treatment is not restricted by defect size within the relevant clinical parameters.

Deciding which step on the ladder fits your hip

Three quite different clinical situations call for three different interventions — and the distinction is sharper than it might initially appear.

If your hip has flared acutely — swollen, painful to weight-bear, or not responding to rest — corticosteroid is the appropriate first step. It also serves a diagnostic purpose: a clear response to an image-guided intra-articular injection confirms that the hip joint itself, rather than a tendon, bursa, or lumbar nerve root, is generating the pain. That is a narrow but clinically important role, separate from long-term management.

If imaging shows mild-to-moderate OA spread across the joint surface — cartilage thinning broadly rather than a defined focal lesion — and the aim is sustained symptom control over several months, hyaluronic acid is the better-matched option. It acts within the joint space; its role is lubrication and symptomatic relief, which is exactly what that pattern of OA requires.

If a scan has identified a focal cartilage defect with a mappable boundary, and the goal is biological repair rather than temporary relief, ChondroFiller injection occupies a qualitatively different position: placed into the defect itself, not dispersed into the joint cavity.

One evidence gap is worth naming honestly: there is no published randomised controlled trial directly comparing HA and ChondroFiller in the hip joint. The distinction between these two rungs rests on mechanism and indication — supported by separate bodies of evidence — rather than on head-to-head hip-specific trial data. That limitation should factor into any candid clinical discussion.

Determining which step applies to a specific hip — taking into account OA grade, defect type, symptom pattern, and treatment goal — requires a structured assessment of imaging and clinical history. Lincolnshire Hip accepts patients for that assessment without a GP referral.

Hip injection assessment at Lincolnshire Hip

Patients across Lincolnshire and the wider East Midlands can access all three rungs of this hip injection ladder — corticosteroid, hyaluronic acid, and ChondroFiller injection — at Lincolnshire Hip's clinics in Sleaford and Grantham. The service is led by Professor Paul Y. F. Lee, whose published work on non-pharmacological and non-surgical approaches to hip pain reflects the same preservation-first philosophy that underpins the injection pathway. PRP is also available as a supplementary orthobiologic option for suitable patients; it sits alongside the three-rung framework described in this article rather than as a named step within it.

Every injection is delivered under ultrasound guidance — a technical requirement that is especially important at the hip given the depth of the joint. Before any injection is chosen, a structured assessment reviews imaging to establish OA grade, defect profile, and which step, if any, fits the clinical picture.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without GP referral for hip injection assessment.